Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
20.32
-0.28 (-1.36%)
At close: Mar 28, 2025, 4:00 PM
20.49
+0.17 (0.82%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Company Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer.
The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab.
Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida.
Summit Therapeutics Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Robert W. Duggan |
Contact Details
Address: 601 Brickell Key Drive, Suite 1000 Miami, Florida 33131 United States | |
| Phone | 305-203-2034 |
| Website | summittxinc.com |
Stock Details
| Ticker Symbol | SMMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001599298 |
| CUSIP Number | 86627T108 |
| ISIN Number | US86627T1088 |
| Employer ID | 37-1979717 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-Chief Executive Officer, President and Director |
| Robert W. Duggan | Co-Chief Executive Officer and Executive Chairman |
| Manmeet Singh Soni CPA | Chief Operating Officer, Chief Financial Officer and Director |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
| Bhaskar Anand | Chief Accounting Officer and Head of Finance |
| Divya Chari | Head of Global Clinical Operations |
| Dave Gancarz | Chief Business and Strategy Officer |
| Dr. Betty Y. Chang Ph.D. | Head of Research, Oncology and Inflammation |
| Dr. Fong Clow | Chief Biometrics Officer |
| Shelley D. Spray | Chief Education and Brand Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2025 | 10-K | Annual Report |
| Feb 24, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 8-K | Current Report |
| Jan 21, 2025 | UPLOAD | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 19, 2024 | UPLOAD | Filing |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 26, 2024 | D | Notice of Exempt Offering of Securities |
| Sep 19, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |